Development and validation of a training course on proton pump inhibitor deprescription for general practitioners in a rural continuing medical education program: a pilot study.
Humans
Pilot Projects
Proton Pump Inhibitors
/ therapeutic use
Education, Medical, Continuing
General Practitioners
/ education
Rural Health Services
Deprescriptions
Male
Female
Practice Patterns, Physicians'
/ statistics & numerical data
Adult
Inappropriate Prescribing
/ prevention & control
Curriculum
Middle Aged
Program Development
Continuing medical education
Deprescription
Proton Pump inhibitor
Rural medicine
Journal
BMC medical education
ISSN: 1472-6920
Titre abrégé: BMC Med Educ
Pays: England
ID NLM: 101088679
Informations de publication
Date de publication:
27 Oct 2024
27 Oct 2024
Historique:
received:
30
05
2024
accepted:
17
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
Despite being cornerstone medications for managing gastrointestinal disorders, proton pump inhibitors (PPI) have raised concerns due to inappropriate prescribing and overutilization, their potential side effects, and interactions with other medications. General practitioners (GPs) provide long-term patient follow-up and are targets to promote PPI deprescribing to reach the widest possible population. GPs practicing in rural settings encounter unique challenges as their numbers dwindle and their workload increases. Hence, targeted educational interventions are crucial to promote appropriate prescribing practices in such underserved areas. We developed a continuing medical education (CME) program focused on PPI deprescribing for GPs in rural settings. The program comprised of an interactive training session featuring clinical cases, an open discussion, and distribution of educational materials. We assessed the program's effectiveness using a two-level Kirkpatrick model, evaluating participant satisfaction and knowledge levels through pre- and post-course questionnaires. Thirty-three GPs participated, with 61.9% working in semi-rural and 38.1% in rural areas (21 responded to the 1st questionnaire, 14 to the 2nd ). Median medical experience was 6 years, with 61.9% serving as internship supervisors. Despite 95.2% acknowledging PPI overprescription, none had previously participated in dedicated PPI CME programs. The open discussion session provided valuable insights into various topics related to PPI use and gastrointestinal health. Participants expressed high satisfaction with the program (average rating of 9.1/10) and 92.9% reported changes in practice, including increased awareness of inappropriate PPI prescriptions. Indeed, 92.9% of GPs identified inappropriate PPI use following the course. 57.1% of participants utilized the provided educational materials. The main practice changes observed included an increased reassessment rate of PPI indications (71.4% at each renewal after vs. 19% before, 28.6% non-systematically after vs. 66.8% before, 0% rarely after vs. 14.3% before; p = 0.006), the necessity for more than one consultation to deprescribe (64.3% after vs. 23.8% before; p = 0.021), systematic utilization of gradual cessation of PPI (100% vs. 61.9%; p = 0.039) and more frequent use of additional medication (92.9% vs. 57.1%; p = 0.022), primarily antiacids (92.3%). Our study underscores the effectiveness of targeted CME programs in promoting appropriate prescribing practices and enhancing knowledge among GPs in rural settings. Despite the challenges encountered in deprescribing PPI, the program facilitated proactive approaches in managing treatment discontinuation failures. Tailored educational interventions are essential for mitigating medication prescribing challenges and improving patient outcomes in rural primary care settings. Not applicable.
Sections du résumé
BACKGROUND
BACKGROUND
Despite being cornerstone medications for managing gastrointestinal disorders, proton pump inhibitors (PPI) have raised concerns due to inappropriate prescribing and overutilization, their potential side effects, and interactions with other medications. General practitioners (GPs) provide long-term patient follow-up and are targets to promote PPI deprescribing to reach the widest possible population. GPs practicing in rural settings encounter unique challenges as their numbers dwindle and their workload increases. Hence, targeted educational interventions are crucial to promote appropriate prescribing practices in such underserved areas.
METHODS
METHODS
We developed a continuing medical education (CME) program focused on PPI deprescribing for GPs in rural settings. The program comprised of an interactive training session featuring clinical cases, an open discussion, and distribution of educational materials. We assessed the program's effectiveness using a two-level Kirkpatrick model, evaluating participant satisfaction and knowledge levels through pre- and post-course questionnaires.
RESULTS
RESULTS
Thirty-three GPs participated, with 61.9% working in semi-rural and 38.1% in rural areas (21 responded to the 1st questionnaire, 14 to the 2nd ). Median medical experience was 6 years, with 61.9% serving as internship supervisors. Despite 95.2% acknowledging PPI overprescription, none had previously participated in dedicated PPI CME programs. The open discussion session provided valuable insights into various topics related to PPI use and gastrointestinal health. Participants expressed high satisfaction with the program (average rating of 9.1/10) and 92.9% reported changes in practice, including increased awareness of inappropriate PPI prescriptions. Indeed, 92.9% of GPs identified inappropriate PPI use following the course. 57.1% of participants utilized the provided educational materials. The main practice changes observed included an increased reassessment rate of PPI indications (71.4% at each renewal after vs. 19% before, 28.6% non-systematically after vs. 66.8% before, 0% rarely after vs. 14.3% before; p = 0.006), the necessity for more than one consultation to deprescribe (64.3% after vs. 23.8% before; p = 0.021), systematic utilization of gradual cessation of PPI (100% vs. 61.9%; p = 0.039) and more frequent use of additional medication (92.9% vs. 57.1%; p = 0.022), primarily antiacids (92.3%).
CONCLUSIONS
CONCLUSIONS
Our study underscores the effectiveness of targeted CME programs in promoting appropriate prescribing practices and enhancing knowledge among GPs in rural settings. Despite the challenges encountered in deprescribing PPI, the program facilitated proactive approaches in managing treatment discontinuation failures. Tailored educational interventions are essential for mitigating medication prescribing challenges and improving patient outcomes in rural primary care settings.
TRIAL REGISTRATIONS
BACKGROUND
Not applicable.
Identifiants
pubmed: 39465370
doi: 10.1186/s12909-024-06215-2
pii: 10.1186/s12909-024-06215-2
doi:
Substances chimiques
Proton Pump Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1221Informations de copyright
© 2024. The Author(s).
Références
Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG, Group. Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179.
doi: 10.1186/s12916-016-0718-z
Moraes-Filho JP, Pedroso M, Quigley EMM, PAMES Study Group. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. Aliment Pharmacol Ther. 2014;39:47–56.
doi: 10.1111/apt.12540
Kamboj AK, Patel DA, Yadlapati R. Long-term Proton Pump inhibitor use: review of indications and special considerations. Clin Gastroenterol Hepatol. 2024;0.
Shanika LGT, Reynolds A, Pattison S, Braund R. Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol. 2023;79:1159–72.
doi: 10.1007/s00228-023-03534-z
Haute Autorité de Santé. Recommandation de bonnes pratiques: Bon usage des inhibiteurs de la pompe à protons. Haute Autorité de Santé. 2022. https://www.has-sante.fr/jcms/p_3372966/fr/fiche-bon-usage-des-inhibiteurs-de-la-pompe-a-protons-ipp . Accessed 5 Mar 2024.
Shah ED, Chan WW, Jodorkovsky D, Lee Lynch K, Patel A, Patel D et al. Optimizing the Management Algorithm for Heartburn in General Gastroenterology: cost-effectiveness and cost-minimization analysis. Clin Gastroenterol Hepatol. 2024;22(10):2011–2022.e5. https://doi.org/10.1016/j.cgh.2023.08.026
Lata T, Trautman J, Townend P, Wilson RB. Current management of gastro-oesophageal reflux disease-treatment costs, safety profile, and effectiveness: a narrative review. Gastroenterol Rep (Oxf). 2023;11:goad008.
doi: 10.1093/gastro/goad008
Vaezi MF, Yang Y-X, Howden CW. Complications of Proton Pump inhibitor therapy. Gastroenterology. 2017;153:35–48.
doi: 10.1053/j.gastro.2017.04.047
Haute Autorité de Santé. Comission de la Transparence: Rapport d’évaluation des inhibiteurs de la pompe à protons (spécialités et génériques). 2015. https://www.has-sante.fr/upload/docs/application/pdf/2020-11/rapport_reevaluation_ipp_avisdef_cteval493.pdf . Accessed 5 Mar 2024.
Gendre P, Mocquard J, Artarit P, Chaslerie A, Caillet P, Huon J-F. (De)prescribing of proton pump inhibitors: what has changed in recent years? An observational regional study from the French health insurance database. BMC Prim Care. 2022;23:341.
doi: 10.1186/s12875-022-01941-2
Agence nationale de sécurité du médicament et des produits de santé (ANSM). Utilisation des inhibiteurs de la pompe à protons (IPP) Étude observationnelle à partir des données du SNDS, France. 2015. 2018.
The National Council of Hepato-Gastroenterology. White book of hepato-gastroenterology. 2020.
French Medical Council. Atlas de la démographie médicale 2023. Conseil National de l’Ordre des Médecins. 2023. https://www.conseil-national.medecin.fr/publications/communiques-presse/publication-latlas-demographie-medicale-2023 . Accessed 5 Mar 2024.
Bloom BS. Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews. Int J Technol Assess Health Care. 2005;21:380–5.
doi: 10.1017/S026646230505049X
Smidt A, Balandin S, Sigafoos J, Reed VA. The Kirkpatrick model: a useful tool for evaluating training outcomes. J Intellect Dev Disabil. 2009;34:266–74.
doi: 10.1080/13668250903093125
Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on De-prescribing of Proton Pump inhibitors: Expert Review. Gastroenterology. 2022;162:1334–42.
doi: 10.1053/j.gastro.2021.12.247
Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30:793–807.
doi: 10.1007/s40266-013-0106-8
Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016;28:420–5.
doi: 10.1097/BOR.0000000000000291
Porter KM, Hoey L, Hughes CF, Ward M, Clements M, Strain J, et al. Associations of atrophic gastritis and proton-pump inhibitor drug use with vitamin B-12 status, and the impact of fortified foods, in older adults. Am J Clin Nutr. 2021;114:1286–94.
doi: 10.1093/ajcn/nqab193
Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton Pump inhibitor and Histamine-2 receptor antagonist Use and Iron Deficiency. Gastroenterology. 2017;152:821–e8291.
doi: 10.1053/j.gastro.2016.11.023
Buon M, Gaillard C, Martin J, Fedrizzi S, Mosquet B, Coquerel A, et al. Risk of proton pump inhibitor-induced mild hyponatremia in older adults. J Am Geriatr Soc. 2013;61:2052–4.
doi: 10.1111/jgs.12534
Gong EJ, Jung H-K, Lee B, Hong J, Kim JW, Shin CM, et al. Proton pump inhibitor use and the risk of metachronous gastric cancer after H. Pylori eradication in patients who underwent endoscopic resection for gastric neoplasms: a population-based cohort study. Aliment Pharmacol Ther. 2023;58:668–77.
doi: 10.1111/apt.17676
Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side effects of Long-Term Proton pump inhibitor use: a review. Basic Clin Pharmacol Toxicol. 2018;123:114–21.
Kurlander JE, Kennedy JK, Rubenstein JH, Richardson CR, Krein SL, De Vries R, et al. Patients’ perceptions of Proton Pump inhibitor risks and attempts at discontinuation: a National Survey. Am J Gastroenterol. 2019;114:244–9.
doi: 10.14309/ajg.0000000000000061
Boghossian TA, Rashid FJ, Thompson W, Welch V, Moayyedi P, Rojas-Fernandez C, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3:CD011969.
Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Th Adv Gastroenterol. 2012;5:219–32.
doi: 10.1177/1756283X12437358
Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014;31:625–30.
doi: 10.1093/fampra/cmu050
Nguyen-Soenen J, Jourdain M, Fournier J-P. Development of Patient Education Material for Proton pump inhibitor deprescribing: a mixed-methods study. Ann Pharmacother. 2022;56:800–8.
doi: 10.1177/10600280211046630
Nguyen-Soenen J, Rat C, Fournier J-P. Suitability of patient education materials on proton-pump inhibitors deprescribing: a focused review. Eur J Clin Pharmacol. 2020;76:17–21.
doi: 10.1007/s00228-019-02779-x
Nguyen-Soenen J, Rat C, Gaultier A, Schirr-Bonnans S, Tessier P, Fournier J-P. Effectiveness of a multi-faceted intervention to deprescribe proton pump inhibitors in primary care: protocol for a population-based, pragmatic, cluster-randomized controlled trial. BMC Health Serv Res. 2022;22:219.
doi: 10.1186/s12913-022-07496-3
Mari A, Marabotto E, Ribolsi M, Zingone F, Barberio B, Savarino V, et al. Encouraging appropriate use of proton pump inhibitors: existing initiatives and proposals for the future. Expert Rev Clin Pharmacol. 2023;16:913–23.
doi: 10.1080/17512433.2023.2252327
Farrell B, Richardson L, Raman-Wilms L, de Launay D, Alsabbagh MW, Conklin J. Self-efficacy for deprescribing: a survey for health care professionals using evidence-based deprescribing guidelines. Res Social Adm Pharm. 2018;14:18–25.
doi: 10.1016/j.sapharm.2017.01.003
Cloutier MM, Tennen H, Wakefield DB, Brazil K, Hall CB. Improving Clinician Self-Efficacy does not increase Asthma Guideline Use by Primary Care clinicians. Acad Pediatr. 2012;12:312–8.
doi: 10.1016/j.acap.2012.04.004